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Abstract
Background: Chronic central serous chorioretinopathy (cCSC) is an eye disease characterized by an accumulation
of serous fluid under the retina. It is postulated that this fluid accumulation results from hyperpermeability and
swelling of the choroid, the underlying vascular tissue of the eye, causing a dysfunction of the retinal pigment
epithelium. This fluid accumulation causes neuroretinal detachment. A prolonged neuroretinal detachment in the
macula can lead to permanent vision loss. Therefore, treatment is aimed primarily at achieving resolution of
subretinal fluid, preferably within the first 4 months after diagnosis of the disease. A broad spectrum of treatment
modalities has been investigated in cCSC, but no consensus exists on the optimal treatment of cCSC. Currently,
photodynamic therapy (PDT) and high-density subthreshold micropulse laser treatment (HSML) are among the
most frequently cited treatments in obtaining successful neuroretinal reattachment.
Methods/Design: This is a randomized, controlled, open-label, multicenter trial comparing the efficacy of half-dose
PDT to HSML in treating patients with cCSC. A total of 156 patients will be recruited, 78 patients in each treatment
arm, with a maximum follow-up duration of 8 months after the first treatment. A complete ophthalmological
examination with vision-related quality of life (NEI VFQ-25) and stress questionnaires, will be performed at baseline,
6 to 8 weeks after the first treatment, 6 to 8 weeks after a second treatment (if necessary), and at the final follow-up
visit at 7 to 8 months after the first treatment. Treatment visits will be scheduled within 3 weeks after the baseline
visit, and within 3 weeks after the first control visit, if a second treatment is required.
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Discussion: Both half-dose PDT and HSML may be effective treatments in cCSC, but because of the lack of
prospective randomized controlled trials, which treatment should be the first choice remains unclear. The aim of
this study is to compare the efficacy of half-dose PDT to HSML. The primary endpoint to evaluate efficacy will be a
complete absence of subretinal fluid on optical coherence tomography after treatment. Secondary functional
endpoints include change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity,
retinal sensitivity on microperimetry, and NEI VFQ-25 questionnaire of visual functioning.
Registration number Institutional Review Board (CMO Arnhem-Nijmegen, the Netherlands): 2013/203 NL nr.:
41266.091.13
Trial registration: ClinicalTrials.gov identifier: NCT01797861. Date of registration: 21 February 2013.
Keywords: chronic central serous chorioretinopathy, half-dose photodynamic therapy, high-density subthreshold
micropulse laser, prospective, randomized controlled, multicenter, trial, verteporfin
Background
Chronic central serous chorioretinopathy
Central serous chorioretinopathy (CSC) is a relatively
common early-onset eye disease, characterized by an ac-
cumulation of leaked serous fluid under the retina, caus-
ing a detachment of the neuroretina. This subretinal
fluid (SRF) leakage results from dysfunction of the ret-
inal pigment epithelium (RPE), and the presence of
choroidal congestion and thickening and hyperperme-
ability of the choroid implies an important role for chor-
oidal abnormalities as an underlying cause for RPE
dysfunction and SRF leakage in CSC [1–4].
Two main subtypes of CSC are generally distinguished:
acute and chronic CSC (cCSC) [1–7]. Patients with
acute CSC present with a sudden and marked central vi-
sion loss because of SRF leakage in the macula; this is
due to a focal leak in the RPE that is visible on fluores-
cein angiography. Acute CSC generally has a favorable
prognosis because the SRF often disappears spontan-
eously within 2 to 3 months, with either complete or al-
most complete recovery of vision. In contrast, cCSC is
typically not self-limiting, and SRF persists for more
than 3 months. Also, cCSC patients present at an older
age, with a disease onset that is generally experienced as
less sudden, and bilaterality in chronic CSC is common
[8]. A history of acute CSC and/or an episode of acute
vision loss compatible with acute CSC is present only
rarely in chronic CSC patients [2, 8], which also points
to a distinction between acute and chronic CSC. Patients
with the cCSC phenotype have more diffuse multifocal
leakage on fluorescein and indocyanine green (ICG)
angiography, as well as irregularly distributed widespread
RPE changes associated with varying degrees of more in-
distinct leakage on angiography (Fig. 1). Persistent ser-
ous neuroretinal detachments can cause progressive
and irreversible photoreceptor damage, resulting in a
poorer visual prognosis of cCSC as compared to acute
CSC [2, 9, 10]. The etiology of CSC is largely un-
known, but the use of corticosteroids is a risk factor,
and possibly elevated cortisol levels, stress, “type A”
personality, and pregnancy are also possible risk fac-
tors [1, 11–14]. The incidence of CSC is approximately
six times higher in men than in women [1], although
this male-to-female proportion seems to be less
pronounced in cCSC and steroid-associated CSC. Re-
cently, single-nucleotide polymorphisms in the Com-
plement Factor H and ARMS2 have been found to be
associated with cCSC [15, 16].
A prolonged neuroretinal detachment in the macula
leads to progressive and permanent central visual loss
due to photoreceptor atrophy. In addition, Piccolino
et al. described the occurrence of not only SRF, but also
of intraretinal fluid accumulations, posterior cystoid de-
generation, and prolonged neuroretinal detachments in
severe cCSC cases [17]. Nicolo et al. have shown that
this posterior cystoid degeneration is associated with a
Fig. 1 Multimodal imaging in chronic central serous chorioretinopathy.
Examples of fluorescein angiography (FA), indocyanine green (ICG)
angiography and spectral-domain optical coherence tomography
(SD-OCT) in chronic central serous chorioretinopathy (cCSC). (a-c) Right
eye of a patient with cCSC with more widespread leakage on FA (a)
corresponding with hyperfluorescent areas on ICG angiography (b) and
SRF on SD-OCT (c)
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poorer response to photodynamic therapy (PDT) [17, 18].
A loss of visual acuity with image distortion and a loss of
color and contrast vision may have a significant impact on
a patient’s personal and professional life. Early diagnosis
and treatment is important to try to improve the visual
outcome and quality of life, as long-term follow-up studies
have shown that the natural course of cCSC often results
in permanent visual loss [3, 9, 10, 19–25]. Therefore, sev-
eral treatment options have emerged in an attempt to ac-
celerate the resolution of SRF accumulation and to
improve the visual outcome in patients with cCSC. Treat-
ment within 4 months after the onset of the disease has
been advocated by several authors, based on the observa-
tion that permanent visual loss may result from prolonged
duration of disease [2, 3]. Photoreceptor atrophy in the
fovea may occur, even after successful reattachment of the
retina, after a duration of symptoms of approximately
4 months [9]. To date there is no international consensus
on the optimal treatment protocol of cCSC.
Photodynamic therapy in chronic central serous
chorioretinopathy
A number of retrospective studies suggests that in 70 to
100 % of CSC patients, treatment with PDT, using the
photosensitizing drug verteporfin (Visudyne™), is effective
in reducing SRF, with an improvement of retinal anatomy,
visual acuity [18, 26–30], and retinal sensitivity [31–35].
PDT treatment was developed originally as treatment
for neovascular age-related macular degeneration, on
which there are extensive data available [36, 37]. There
are several other retinal diseases for which PDT with
verteporfin is successfully used as an off-label treat-
ment, such as choroidal hemangioma and polypoidal
choroidal vasculopathy [37].
PDT with Visudyne™ (verteporfin for injection) is a
two-stage procedure that first requires the intravenous
administration of verteporfin, followed by the adminis-
tration of non-thermal red light into the affected eye.
Verteporfin is transported in the plasma primarily by li-
poproteins. Once verteporfin is activated by light in the
presence of oxygen, highly reactive, short-lived singlet
oxygen and reactive oxygen radicals are generated. Ver-
teporfin appears to accumulate preferentially in abnor-
mal neovascularization (which is not present in cCSC)
but also in the choroidal vasculature. The latter mechan-
ism is of special interest in the treatment of cCSC be-
cause CSC primarily affects the choroidal circulation,
resulting in multifocal areas of choroidal vascular hyper-
permeability that may finally result in the accumulation
of SRF. The therapeutic effect of PDT in cCSC is
thought to result from short-term choriocapillaris hypo-
perfusion and long-term choroidal vascular remodeling,
leading to reduction in choroidal congestion, vascular
hyperpermeability, and extravascular leakage [38–40].
As mentioned previously, there is no international
consensus on the optimal treatment protocol of cCSC.
Nevertheless, PDT has emerged as the treatment of
choice in many centers worldwide, based on the high
rate of anatomic success, the increase of visual acuity,
improvement in retinal sensitivity, and an excellent
safety profile reported in many retrospective studies
[3, 41–43]. The PDT strategies that are generally used
are either with half the dose of verteporfin and full
fluency (energy) of laser treatment, half the fluency
level and the full dose of verteporfin, or half the treatment
time using the full dose of verteporfin and full fluency, as
compared to the original protocol that was used for neo-
vascular age-related macular degeneration. These PDT
strategies that use either half-dose of half-fluency treat-
ment have been developed because a combination of the
dosage and fluency that was originally used for the treat-
ment of neovascular age-related macular degeneration
showed a potentially higher risk of developing choroidal
ischemia and retinal atrophic changes [36, 44–46]. The
half-dose or half-fluency PDT strategies, however, have
been shown to be safe and effective in relatively large
retrospective studies and in one noncontrolled, nonrando-
mized prospective study by Chan et al. in cCSC patients
with sufficient follow-up periods [3, 27, 29, 41].
Therefore, tailoring the therapy to obtain the maximal
treatment effect with minimal toxicity is essential in
treating patients with CSC. By reducing the dose of ver-
teporfin, studies have demonstrated that the potential
retinal damage caused by PDT can be minimized while
the photodynamic effects in inducing choroidal vascula-
ture changes required for treating CSC remain sufficient
[2, 3, 18, 26–30, 41, 47]. None of the patients treated
with this half-dose PDT protocol experienced any sys-
temic adverse event (AE) associated with verteporfin in-
fusion [27]. In several relatively large retrospective
studies on half-dose PDT in CSC, none of the patients
had any subjective or objective drop in vision immedi-
ately after PDT or at subsequent follow-up visits [18,
26–30]. This “safety-enhanced” protocol with half-dose
verteporfin appeared to be one of the safest and effective
treatment options in patients with active cCSC [23, 41]. In
conclusion, a relatively large body of well-documented
retrospective studies indicates that half-dose PDT is able
to yield positive functional and anatomic outcomes while
at the same time reducing the potential AEs associated
with conventional PDT with full-dose verteporfin.
High-density subthreshold micropulse laser therapy as an
alternative treatment in chronic central serous
chorioretinopathy
There are several retrospective studies that indicate that
high-density subthreshold micropulse laser (HSML)
therapy may be effective in 41 to 58 % of CSC patients
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[18, 48]. HSML treatment using a 810 nm wavelength is
an established treatment option for a broad range of ret-
inal diseases [49]. In this treatment, no photosensitizing
drug is needed. This relatively new laser treatment mo-
dality may prevent damage to the neural retina that oc-
curs in conventional (non-PDT) laser techniques by
raising the temperature of the RPE below the protein-
denaturation-threshold so that the thermal wave that
reaches the neural retina is insufficient to cause either
damage or a clinically visible end-point (opacified ret-
ina). It is different from subthreshold continuous wave
in that more energy can be delivered to the RPE without
neuroretinal damage using multiple short pulses. In con-
trast, in the continuous wave mode of conventional laser
therapy, the laser energy is delivered with a single pulse
with a duration of exposure of 0.1 to 0.5 s, most of the
energy is absorbed by the RPE and the heat energy is
transferred to the neurosensory retina leading to transi-
ent retinal swelling (visible end-point). As a result, con-
ventional laser application in the macula may cause
damage to the neuroretina and RPE, leading to central
scotomas and possibly loss of visual acuity. Previous
studies have shown that conventional laser treatment in
CSC, in contrast to HSML treatment and half-dose PDT
treatment, does not improve visual acuity, may cause
photoreceptor damage, and may induce choroidal neo-
vascularization [3]. Recently, studies using a relatively
new 577 nm wavelength micropulse laser in subthresh-
old mode have also shown possible efficacy in the treat-
ment of cCSC [50, 51].
Outline of proposed clinical trial
The PLACE study is a superiority study because retro-
spective studies suggest that the rate of anatomical and
functional success of PDT treatment might be higher
than the success of HSML treatment. Therefore, a half-
dose PDT treatment arm is challenged against a treat-
ment arm of HSML treatment.
In this study, we want to define treatment success not
only on the basis of structural parameters (anatomic suc-
cess, for example, the absence of SRF after treatment), but
also based on functional vision-related endpoints, which
are most important from a patient’s perspective. These
functional vision-related endpoints will include best-
corrected visual acuity (BCVA), retinal sensitivity on
microperimetry and score on a validated visual function
questionnaire (the NEI-VFQ-25 questionnaire) http://
www.psy.cmu.edu/~scohen/ [52].
With the results of this study, we hope to establish a
strong scientific foundation for further research on the
optimal treatment of patients with cCSC to improve the
visual outcome and quality of life of this relatively fre-
quently occurring eye disease.
Objectives
Primary objective
The primary objective of this study is to investigate
whether treatment of cCSC patients with macular SRF
on optical coherence tomography (OCT) with half-dose
PDT results in more eyes with an absence of SRF on the
OCT as compared to HSML treatment.
Secondary objectives
The secondary objectives are to investigate the clinical
outcome comparing half-dose PDT treatment with
HSML treatment in patients with SRF due to active leak-
age in cCSC, based on evaluation of BCVA; the retinal
sensitivity on microperimetry; and the subjective success
score on the NEI-VFQ-25 questionnaire.
Methods/Design
Summary of trial design
This study is a multicenter, prospective, randomized,
controlled, open-label study that will compare the effi-
cacy and safety of two treatments in patients with cCSC.
The first group of patients will receive half-dose PDT
treatment. The second group of patients will receive
810 nm HSML treatment. Each patient will receive at
least one treatment but may be eligible to receive a sec-
ond treatment during follow-up (Fig. 2), which will be
Fig. 2 Study flow chart
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the same type of treatment as the first treatment: either
half-dose PDT treatment or HSML treatment.
Potential eligible patients will be identified in one of
five specialist ophthalmology trial sites, each led by one
of the principal investigators (PIs).
Fundus photographs, fluorescein angiograms, ICG an-
giograms and OCT images collected at the screening visit
will be sent to a central reading center (CRC). The CRC
will review these images to confirm subject eligibility
based on the characteristics specified in the inclusion and
exclusion criteria. Once eligibility has been confirmed by
the CRC, all other inclusion and exclusion criteria have
been met at the baseline visit, and informed consent has
been obtained, patients will be enrolled in the trial.
There are nine examinations that will be performed at
the baseline assessment, 6 to 8 weeks after treatment (at
evaluation visit 1, and if a second treatment is required, at
evaluation visit 2), and at the final visit (7 to 8 months
after start of the treatment). The six anatomical assess-
ments include ophthalmoscopy, fundus photography,
OCT, autofluorescence imaging, fluorescein angiography,
and ICG angiography. The three functional assessments
include visual acuity measurement, microperimetry, and a
questionnaire on vision-related functioning.
Enrolled patients will be randomized at a 1:1 ratio
to receive either half-dose PDT treatment or HSML
treatment.
The total number of visits per patient is five (in case
of one required treatment) or seven (in case of two re-
quired treatments). The duration of participant partici-
pation within the study is 7 to 8 months (Fig. 2).
An overview of the assessments in the trial are as
follows:
1. Ophthalmoscopy
This examination will be performed by one of the
ophthalmologists to confirm the diagnosis. The
pupils will have to be dilated with 1.0 % tropicamide
and 2.5 % phenylephrine for ophthalmoscopy to be
performed.
2. Fundus photography
The fundus photography will be taken with a
Topcon TRC-50 series fundus camera. The photo-
graphs will be taken with a 50°-field centered on the
area of the macula.
3. Optical coherence tomography (OCT) imaging
Patients will be examined by noninvasive OCT
imaging. OCT shows the different layers of the
retina and is the imaging modality of choice to
visualize subretinal and intraretinal fluid, for
instance in cCSC. This examination is performed
during mydriasis (dilated pupils). OCT imaging will
be carried out with a Spectralis HRA +OCT
(Heidelberg Engineering, Heidelberg, Germany).
4. Fundus autofluorescence imaging
Fundus autofluorescence is a noninvasive imaging
technique that is able to register changes of
autofluorescence intensity in the retina, for instance
due to accumulation of lipofuscin in the RPE.
Fundus autofluorescence imaging will be carried out
with a Spectralis HRA +OCT (Heidelberg
Engineering, Heidelberg, Germany).
5. Fluorescein and indocyanine green (ICG)
angiography
To perform fluorescein and ICG angiography,
intravenous injection of fluorescein and ICG is
required. During the angiography procedure, both
(fluorescein and ICG) dyes may be injected at the
same time or separately. Fluorescein reveals the
retinal vasculature and may show areas of fluid
leakage through the RPE, whereas the ICG dye
images the choroidal vasculature. The visualization
of both the retinal vasculature and RPE permeability
(by fluorescein angiography) and choroidal
vasculature (by ICG angiography) is essential to
image the areas of abnormal anatomy and leakage
that may guide treatment. Images of the study eye
are taken at set times: 0 to 1 minute (several images
covering the arterial and venous filling phases),
3 minutes, 6 minutes, 10 minutes, 15 minutes, and
20 minutes. Images of the nonstudy eye will be
taken at 1 minute, 6 minutes, and 20 minutes. All
images will be acquired with Spectralis HRA +OCT
(Heidelberg Engineering, Heidelberg, Germany).
6. Best-corrected visual acuity (BCVA)
BCVA will be assessed for both eyes at all evaluation
visits. To measure BCVA, early treatment diabetic
retinopathy study (ETDRS) visual acuity testing
charts will be used at a distance of 4 meters.
7. Microperimetry
All patients will be examined by noninvasive
microperimetry. This technique is able to measure
retinal sensitivity to light, and follow-up pre- and
post-treatment changes in retinal sensitivity at pre-
determined loci in the macula. By using a reliable
eye tracking system, this microperimetry system is
able to exactly locate the areas of retina that have
been tested previously, in order to ensure testing of
identically the same area at follow-up. Microperime-
try according to a standard protocol takes 5 to 8 -
minutes for each eye and will be performed with
non-dilated pupils.
8. Questionnaires
Each participant will be asked to complete a quality-
of-life questionnaire based on the National Eye
Institute Visual Function Questionnaire (NEI-VFQ-25)
[52], and the Cohen Stress Questionnaire [53] [http://
www.centervue.com/product.php?id=639]. NEI-VFQ-
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25 is a reliable and validated 25-item version of the 51-
item National Eye Institute Visual Function Question-
naire [54]. The questionnaire is especially useful in
settings such as clinical trials, where interview length is
an important consideration. The Cohen Stress Ques-
tionnaire is a validated questionnaire indicating the
stress level patients have been exposed to during the
month before disease onset.
There will be standard operating procedures (SOPs)
available to all investigators involved in the trial as well
as in the trial master file for each of the described
examinations.
Primary and secondary endpoints
Primary endpoint
The primary endpoint of this study is to assess if there is
a difference between the efficacy of half-dose PDT treat-
ment versus the HSML treatment in patients with cCSC.
The assessment of this efficacy will be based on the ana-
tomical effect on OCT: absence of SRF versus persistent
SRF, 6 to 8 weeks after treatment. After all, the absence
or presence of fluid under the retina on the OCT scan is
a direct reflection of the activity of the disease in these
patients.
Secondary endpoints
For secondary endpoints, we will mainly look at three
parameters that reflect the patient’s vision-related func-
tioning. These three parameters are a standardized
measurement of BCVA according to the ETDRS stan-
dards, a standardized measurement of sensitivity of the
macula with microperimetry, and a standardized assess-
ment of the patient’s vision-related quality of life using a
validated questionnaire, the NEI-VFQ-25.
The secondary endpoints that will be assessed as a re-
flection of functional improvement after treatment in-
clude the following:
1. Number of second treatments needed in each
treatment arm.
2. Mean change from baseline in ETDRS BCVA in the
study eye at 6 to 8 weeks after treatment visit 1 and
at 7 to 8 months after treatment visit 1, among the
two treatment modalities.
3. Mean change from evaluation visit 1 in ETDRS
BCVA in the study eye at final evaluation (7 to
8 months after treatment visit 1), among those who
required one treatment and those who required a
second treatment, and among the two treatment
modalities overall.
4. Mean change from baseline in retinal sensitivity on
microperimetry in the study eye at 6 to 8 weeks
after treatment visit 1 and at 7 to 8 months after
treatment visit 1 among the two treatment
modalities.
5. Mean change from baseline in the NEI-VFQ-25
questionnaire at 6 to 8 weeks after treatment visit 1
and at 7 to 8 months after treatment visit 1 among
the two treatment modalities.
6. An absence of SRF on evaluation with OCT
scanning as compared to HSML treatment at 7 to
8 months follow-up after successful treatment (after
treatment visit 1; “success” defined as an absence of
SRF on OCT at 6 to 8 weeks after treatment).
Trial participants
Overall description of the trial participants
This study will enroll subjects with cCSC with active leak-
age of fluid under the retina as evidenced on OCT scan-
ning and further supported by findings on fluorescein
angiography and ICG angiography, in at least one eye. If
both eyes are eligible, then the eye with the longer dur-
ation of disease will be used as the study eye, except in
cases where the disease is present for more than
18 months. In the latter case, which is an exclusion criter-
ion, the other eye will be eligible for inclusion if the dis-
ease has been active for less than 18 months. If the
nonstudy eye also has active disease, the choice to treat
and the type of treatment in this eye may be chosen freely
at the discretion of the responsible ophthalmologist.
Before enrolment, each subject must meet all of the
following inclusion criteria and none of the exclusion
criteria and agree to comply with the study require-
ments, including completion of all of the study visits.
Inclusion criteria
The inclusion criteria are as follows:
1. Male and female patients ≥18 years of age who are
able to give written informed consent.
2. Active cCSC.
3. Subjective visual loss >6 weeks, interpreted as onset
of active disease.
4. SRF that includes the fovea on OCT scanning at
baseline examination. Note: SRF does not have to
include fovea on OCT to be eligible for treatment at
control visit 1 as long as there is persistent SRF in
the macula, which is interpreted as persistently
active disease.
5. Hyperfluorescent areas on ICG angiography.
6. ≥ 1 ill-defined hyperfluorescent leakage areas on
fluorescein angiography with RPE window defect(s)
that are compatible with cCSC.
Exclusion criteria
The participant may not enter the study if any of the fol-
lowing apply:
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1. Any previous treatments for active CSC in the study
eye.
2. Current treatment with corticosteroids (topical or
systemic), corticosteroid use within 3 months before
the possible start of trial treatment, or anticipated
start of corticosteroid treatment within the first 7 to
8 months from the start of the trial period.
3. Evidence of other diagnosis that can explain serous
SRF or visual loss.
4. BCVA <20/200 (Snellen equivalent).
5. Profound chorioretinal atrophy in central macular
area on ophthalmoscopy and OCT.
6. Myopia >6D.
7. Visual loss and/or serous detachment on OCT
<6 weeks.
8. Continuous and/or progressive visual loss
>18 months or serous detachment on OCT
>18 months.
9. No hyperfluorescence on ICG angiography.
10.Intraretinal edema on OCT.
11.Contraindications (relative) for PDT treatment
(pregnancy, porphyria, severely disturbed liver
function). Pregnancy will not be routinely tested in
female patients, but the possibility of pregnancy will
be discussed during eligibility screening.
12.Contraindications (relative) for fluorescein
angiography or ICG angiography (known allergies
especially against shellfish, previous reactions).
13.Soft drusen in treated eye or fellow eye, signs of
choroidal neovascularization on ophthalmoscopy
and/or fluorescein angiography/ICG angiography.
Study procedures
Screening and eligibility assessment
Identification of potential participants Potential par-
ticipants with cCSC will be identified in the participating
trial sites, after being referred to the department by the
general practitioner (GP) or referring ophthalmologists
from other hospitals. Before screening, a visual acuity
measurement, dilated ophthalmoscopy, fundus photog-
raphy, OCT of the retina and choroid, autofluorescence
imaging, and fluorescein and ICG angiography will
already have been performed in most patients as part of
standard clinical care. These examinations constitute
most of the baseline examinations and therefore do not
have to be repeated if screening and randomization is
performed within 2 weeks after these examinations.
Screening and baseline examinations/enrolment are per-
formed on the same day if possible. The maximum dur-
ation allowed between screening and randomization is
2 weeks.
In addition to the examinations mentioned previ-
ously, the following information will be collected from
patients who have been consented, at the baseline
assessment; at control visit 1 and, if applicable, at con-
trol visit 2; and at the follow-up visit at 7 to 8 months
after treatment visit 1:
1. Demographic details - the date of birth, gender, race,
smoking and drinking habits will be recorded on
case report forms (CRFs).
2. Medical history - details of any history of disease or
surgical interventions will be recorded on CRFs.
3. Concomitant medication - all over-the-counter or
prescribed medication, vitamins, and/or herbal sup-
plements will be recorded on CRFs.
Informed consent
The study will be discussed with the subject. The patient
information sheet will be given to the patient at the
screening visit, and the patient will be asked to contact
us if he/she is willing to take part. A subject wishing to
participate must give written informed consent prior to
any study-related procedures or change in treatment.
The participant must personally sign and date the latest
approved version of the informed consent form before
any study-specific procedures are performed. Written
and verbal versions of the participant information and
informed consent will be presented to the participants,
detailing the exact nature of the study, the implications
and constraints of the protocol, the known side effects,
and any risks involved in taking part. It will be clearly
stated that the participant is free to withdraw from the
study at any time for any reason without prejudice to fu-
ture care, and with no obligation to give the reason for
withdrawal.
The participant will be allowed as much time as
wished to consider the information, and the opportunity
to question the investigator, their GP or other independ-
ent parties to decide whether they will participate in the
study. Written informed consent will then be obtained
by means of the participant’s dated signature and dated
signature of the person who presented and obtained the
informed consent. The person who obtained the consent
must be suitably qualified and experienced and have
been authorized to do so by the chief/principal investiga-
tor. A copy of the signed informed consent will be given
to the participants. The original signed form will be
retained at the study site, and an additional copy will re-
main in the patient notes.
Randomization
Subject numbers will be assigned sequentially as each
subject enters the study.
The subjects will be assigned to a study treatment by
a web-based random numbers generator using block
randomization without minimization. This application will
be specially designed for this study by the Department of
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Epidemiology, Biostatistics and Health Technology As-
sessment of the Radboud University Nijmegen Medical
Center (Nijmegen, the Netherlands). Randomization will
be performed at the same visit as the baseline visit. The
randomization schedule is designed by a statistician, and
the randomization codes are kept in the CRF and in the
digital database of the Clinical Research Center Nijmegen
(www.CRCN.nl).
Interventions
Half-dose PDT treatment For this intervention, the pa-
tients need dilated pupils (dilation is achieved with 1.0 %
tropicamide and 2.5 % phenylephrine). All patients will
get an intravenous infusion of 3 mg/m2 verteporfin
(Visudyne ™) (half-dose) over a period of 10 minutes. At
exactly 15 minutes after the start of the infusion, an
anesthetic eye drop is given (oxybuprocaine 0.4 % or
equivalent), a contact lens (a Volk™ PDT lens) is posi-
tioned on the affected eye, and the aiming beam of the
laser is focused on the treatment area. The magnifica-
tion factor is taken into account in the settings of the
PDT machine. The area of treatment is chosen, with
the area of the aiming beam corresponding to the area
of the subsequent laser spot area. The area that has to
be treated is determined based on the hyperfluorescent
area(s) on midphase (approximately 10 minutes) ICG
angiography that correspond(s) to the SRF accumula-
tion in the macula on the OCT scan and hyperfluores-
cent “hot spots” on the midphase (approximately
3 minutes) fluorescein angiogram. The spot size will be
defined based on the diameter of the hyperfluorescent
area on the ICG angiography plus 1 mm (Fig. 3). The
edge of treatment spot has to be at least 200 μm away
from the optic disc rim. The PDT treatment is per-
formed with standard 50 J/cm2 fluency, a PDT laser
wavelength of 689 nm, and a standard treatment dur-
ation of 83 seconds. Care must be taken to treat at
exactly 15 minutes after the start of the infusion, to
maximize the localization of the effect of treatment to
the choroid and minimize possible damage to the adja-
cent retinal structures. The PDT treatment must take
place at least 45 minutes after ICG angiography has
been performed.
HSML treatment For this intervention, the patients
need dilated pupils (dilation achieved with 1.0 % tropica-
mide and 2.5 % phenylephrine). An anesthetic eye drop
is given (oxybuprocaine 0.4 % or equivalent), and a con-
tact glass (for instance a Volk™ area centralis lens) is po-
sitioned on the affected eye. HSML treatment with an
810 nm diode laser will be performed of the areas identi-
fied on midphase ICG angiography. Multiple confluent,
adjacent (nonoverlapping) laser spots will be applied,
covering the leakage area on midphase ICG angiog-
raphy. The number of spots and number of zones
treated depends on the extent of the leakage area(s) on
midphase ICG. The area that has to be treated is deter-
mined based on those hyperfluorescent area(s) on mid-
phase (approximately 10 minutes) ICG angiography
that correspond(s) to SRF accumulation in the macula
on the OCT scan and hyperfluorescent “hot spots” on
the midphase (3 minutes) fluorescein angiogram (Fig. 3).
The treatment will consist of small adjacent laser spots
covering the designated area keeping a distance of
500 μm from the foveal center (corresponding to a laser-
free circular zone of 1000 μm diameter centered on the
fovea).
The following HSML treatment settings will be used: a
power of 1800 mW, a duty cycle of 5 %, frequency of
500 Hz, exposure time of 0.2 s per spot, a spot size of
125 μm, and a minimal distance of the spot from the
fovea of 500 μm [48, 55].
Subthreshold treatment is desired, meaning that no
visible reaction due to laser treatment has to be seen in
the retina. In virtually all patients, a power of 1800 mW
will not produce a visible discoloration of the retina after
application of a laser spot with the aforementioned set-
tings. If retinal discoloration is seen at a power of
1800 mW (corresponding to suprathreshold treatment),
for instance in patients with darkly pigmented fundi, the
power will be reduced with steps of 300 mW until there
is no visible reaction. The first laser “test” spot will al-
ways be applied just outside the macular area.
Retreatment criteria and considerations
At evaluation visit 1, at 6 to 8 weeks after treatment, an
OCT scan of the retina will be performed, among other
imaging examinations. If there still is SRF present in the
macular area, a second treatment will be performed ac-
cording to the protocol within 3 weeks after evaluation
visit 1.
This second treatment (either half-dose PDT or HSML
treatment) will again be guided by the hyperfluorescent
area(s) on the ICG angiography that correspond(s) to
SRF accumulation in the macula on the OCT scan and
the hyperfluorescent “hot spots” on the midphase (ap-
proximately 3 minutes) fluorescein angiogram.
In cases where there is no more SRF under the fovea
but there is persistent fluid within the macular area
encircled by the optic disc and temporal retinal vascular
arcade, retreatment will be performed. The rationale be-
hind this second treatment is that the persistent fluid
may be interpreted as an incomplete treatment response
because SRF accumulation indicates ongoing disease ac-
tivity due to choroidal vascular hyperpermeability and
fluid leakage through the RPE.
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Note that if a patient did not require retreatment at
evaluation visit 1 (=6-8 weeks after treatment visit 1) ac-
cording to the protocol but returns with visual symptoms
in the period between evaluation visit 1 and the follow-up
visit at 7 to 8 months, a regular clinical examination
should be performed that includes at least a measurement
of visual acuity, ophthalmoscopy, and OCT scan to deter-
mine whether SRF has reoccurred. If there is evidence of
recurrence of SRF on OCT (and therefore disease activity),
these findings should be noted in the CRF. In these cases,
additional evaluations compatible with evaluation visit 2
should be performed, and the patient should be planned
for treatment visit 2 (max. 2 to 3 weeks after evaluation
visit 2). Further evaluation will adhere to the retreatment
criteria described above.
However, no treatment is allowed if the patient has
already been treated twice (either with two half-dose
PDT treatments or two HSML treatments) according to
the trial protocol between evaluation visit 1/2 and follow-
up visit (7 to 8 months after treatment visit 1). There are
no data on the usefulness of more than two half-dose
PDT treatments in the same patient with persistent cCSC.
Some authors argue that more than two PDT treatments
in the same eye may increase the risk of complications
such as choroidal ischemia and the formation of choroidal
neovascularization. In the case of HSML treatment, there
also are no reports to suggest that more than two treat-
ments may be useful. That is why a maximum amount of
two of the same treatments is allowed within the trial
period. After completion of the trial (at follow-up visit, 7
Fig. 3 Examples of areas treated in photodynamic therapy and micropulse laser treatment. Examples of imaging features on fluorescein angiography
(FA) and indocyanine green angiography (ICG) angiography in chronic central serous chorioretinopathy (cCSC), and the corresponding treatment areas
for photodynamic therapy (PDT) and high-density subthreshold micropulse laser treatment (HSML). a-b FA of the right eye of a patient showing
hyperfluorescent “hot spots,” indicating leakage inferior of the fovea (a). On ICG angiography, an area of hyperfluorescence, which corresponds to the
hyperfluorescent area on the FA, is seen (b). c-f An example of a PDT spot (white circle) overlapping the hyperfluorescent area on the ICG angiography
plus 1 mm as described in the protocol (c). HSML treatment scheme that would apply to the same eye, in which only the central foveal area
is excluded for treatment (white circle). The hyperfluorescent area on the ICGA is treated with numerous, nonoverlapping adjacent laser spots
(white area) (d)
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to 8 months after treatment visit 1), treatment may be
considered and the treatment modality may be chosen at
the discretion of the treating ophthalmologist.
Definition of end of trial
The end of trial is the date on which the last included
participant has received the last follow-up visit (7 to
8 months after treatment 1).
Discontinuation and withdrawal of participants from study
treatment
Each participant has the right to withdraw from the
study at any time. In addition, the investigator may dis-
continue a participant from the study at any time if the
investigator considers it necessary for any reason includ-
ing the following:
1. Ineligibility (either arising during the study or
retrospective having been overlooked at screening).
2. Significant protocol deviation.
3. Significant non-compliance with study requirements.
4. An AE that requires discontinuation of the study
medication or results in inability to continue to
comply with study procedures.
5. Consent withdrawn.
6. Lost to follow-up.
7. Pregnancy before evaluation visit 1 or 2 (which is a
relative contraindication for angiography).
Pregnancy will not be routinely tested in female
patients, but the possibility of pregnancy will be
discussed during eligibility screening.
Patients suffering from a vision-threatening AE will
also be withdrawn from the study. Withdrawal from the
study will result in exclusion of the data from analysis
from those participants, unless adherence to the proto-
col and follow-up examinations were sufficient to allow
inclusion in the analysis. The reason for withdrawal will
be recorded in the CRF.
If the participant is withdrawn due to an AE, the in-
vestigator will make arrangements for follow-up visits or
telephone calls until the AE has resolved or stabilized.
Sample size calculations showed the need for 78 par-
ticipants per treating arm to find significant values. In
case of a withdrawal, a replacement subject will be in-
cluded. This could cause a delay to the end of the trial
but is not relevant for the outcomes. All subjects with-
drawn from this study will return to normal consultation
at their ophthalmologist of choice.
Safety reporting
Adverse event reporting period The reporting period
during which AEs must be reported is the period from
enrollment to the end of the study period (24 months).
All unresolved AEs must be followed by the trial moni-
tor in contact with the chief investigator and principal
investigators until the events are resolved, the patient is
lost to follow-up, or the AE is otherwise explained. At
the last scheduled study visit, the trial nurse will instruct
each patient to report any subsequent event(s) that the
patient, or the patient’s personal physician, believes
might reasonably be related to prior study treatment.
Such events should be reported to the (previous) treat-
ing ophthalmologist at the department of ophthalmology
of the trial site after the trial has ended. Patients who
withdraw early from the study will be contacted by trial
staff 30 days after their last visit, if the patient gives per-
mission to do so, to ascertain whether any AEs have
occurred.
Definition of adverse events/reactions An adverse
event (AE) or adverse experience includes any untoward
medical occurrence in a patient or clinical investigation
participant who has been administered a medicinal
product, and this event does not necessarily have to have
a causal relationship with this treatment (the study
medication).
An AE can therefore be any unfavorable and unintended
sign (including an abnormal laboratory finding), symp-
tom or disease temporally associated with the use of the
study medication, whether or not the event is considered
related to the study medication.
In the case of an adverse reaction (AR), a causal rela-
tionship between a study medication and an AE is at
least a reasonable possibility (that is, the relationship
cannot be ruled out).
All cases judged by either the reporting medically
qualified professional or the sponsor as having a reason-
able suspected causal relationship to the study medica-
tion qualify as adverse reactions.
These include all untoward and unintended responses
to a medicinal product related to any dose.
ARs could include, for instance, nausea, hypertension,
lower back pain, headache, arthralgia, intravenous in-
jection site reactions (in the case of PDT), cough,
pharyngitis, pneumonia, fever and flu-like symptoms,
hypersensitivity and allergy reactions, vaso-vagal reac-
tions, atrial fibrillation, angina, and sunburn after
sunlight exposure in the first two days after PDT
treatment.
Procedures for recording adverse events/reactions
All AEs occurring during the study observed by the in-
vestigator or reported by the participant, whether or not
attributed to study medication, will be recorded on the
CRF. The following information will be recorded:
description, date of onset and end date, severity,
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assessment of relatedness to study medication, other
suspect drug or device and action taken. Follow-up in-
formation should be provided as necessary. AEs consid-
ered related to the study medication, as judged by a
medically qualified investigator or the sponsor, will be
followed until resolution or until the event is considered
stable. AEs considered related to the study procedure, as
judged by a qualified investigator or the sponsor, will be
followed until resolution or until the event is considered
stable. All related AEs that result in a participant’s with-
drawal from the study or are present at the end of the
study, should be followed up if the patient gives consent
to do so, until a satisfactory resolution occurs.
It will be left to the investigator’s clinical judgment
whether or not an AE is of sufficient severity to require
the participant’s removal from the trial. A participant
may also voluntarily withdraw from treatment due to
what he or she perceives as an intolerable AE. If either
of these occurs, the participant must undergo an end-of-
study assessment and be given appropriate care under
medical supervision until symptoms cease or the condi-
tion becomes stable.
The relationship of AEs to the study medication will
be assessed by a medically qualified investigator, and if
necessary, discussed with the chief investigator. Any
pregnancy occurring during the clinical study and the
outcome of the pregnancy fathered by trial participants,
should be recorded and followed up for congenital ab-
normality or birth defect.
Definitions of serious adverse events/reactions
A serious adverse event (SAE) is any untoward medical
occurrence that at any dose accomplishes the following:
1. Results in death,
2. Is life-threatening, note: the term "life-threatening"
in the definition of "serious" refers to an event in
which the participant was at risk of death at the time
of the event; it does not refer to an event that hypo-
thetically might have caused death if it were more
severe.
3. Requires inpatient hospitalization or prolongation of
existing hospitalization.
4. Results in persistent or significant disability/
incapacity, or is a congenital anomaly/birth defect.
5. Other important medical events. Note: other events
that may not result in death, are not life
threatening, or do not require hospitalization, may
be considered a SAE when, based upon appropriate
medical judgement, the event may jeopardize the
patient and may require medical or surgical
intervention to prevent one of the outcomes listed
above. In this trial, these events are mainly vision-
related.
Vision-threatening adverse events/reactions An AE is
considered to be vision-threatening and is a reportable
SAE if it meets one or more of the following criteria:
1. It caused a decrease in visual acuity of >30 letters
(compared with the last assessment of visual acuity
prior to the most recent treatment) within the
follow-up period of 7 to 8 months.
2. It required surgical intervention.
3. In the investigator’s opinion, it may require medical
intervention to prevent permanent loss of vision.
Causes for such vision-related AEs could include for
instance: RPE tears, subretinal hemorrhage, chor-
oidal neovascularization.
A serious adverse reaction (SAR) is an adverse event
(expected or unexpected) that is both serious and, in the
opinion of the reporting investigator, believed with rea-
sonable probability to be due to one of the study treat-
ments, based on the information provided.
A suspected unexpected serious adverse reaction
(SUSAR) is a serious adverse reaction, the nature or se-
verity of which is not consistent with the applicable
product information (for example, the Investigator’s
brochure for an unapproved investigational product or
summary of product characteristics for an approved
product).
Reporting procedures for serious adverse events
The data monitoring committee (DMC) will undertake a
review of all SAEs for the study. The DMC may hold
electronic meetings. The DMC will meet at intervals and
consider the following:
1. The occurrence and nature of the adverse events.
2. Whether additional information on the adverse
events is required.
3. Taking appropriate action where necessary to halt
trials.
4. Act/advise on incidents occurring between meetings
that require rapid assessment (for example,
SUSARs).
All SAEs will be reported to the DMC within one
working day of discovery or notification of the event. All
SAE information will be recorded on an SAE form,
which will be sent electronically to members of the
DMC. Additional information received for a case (fol-
low-up or corrections to the original case) will be de-
tailed on a new SAE form. After receiving the SAE
report within one working day, the medical monitor will
review possible SAEs weekly, and the DMC has a meet-
ing every three months to review the SAEs, if present.
The chief investigator will also report all SUSARs to the
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competent authorities (TOL/CCMO in the Netherlands,
Bfarm in Germany, and ANSM (Agence Nationale de
Sécurité du Médicament et des Produits de Santé) in
France, the ethics committees concerned, and the host
NHS trust in the United Kingdom. Fatal or life-
threatening SUSARs will be reported within 7 days and
all other SUSARs within 15 days. The Chief Investigator
will also inform all investigators concerned of relevant
information about SUSARs that could adversely affect
the safety of participants.
Trial safety group/data monitoring committee
The DMC will conduct a review of all SAEs for the
study reported every 3 months and cumulatively, if
present. The aims of this review will include the
following:
1. To pick up any trends, such as increases in
unexpected/expected events, and take appropriate
action.
2. To seek additional advice or information from
investigators where required.
3. To evaluate the risk of the trial continuing and take
appropriate action where necessary.
4. To act or advise, through the chairman or other
medical monitors, on incidents occurring between
meetings that require rapid assessment.
This committee, which is based in the coordinating
center in Nijmegen, will receive SAEs within one work-
ing day, and will analyze the available safety data and
study data in a meeting every 3 months, if present.
Description of statistical methods
Univariate analysis
Analysis for the primary endpoint The purpose of this
study is to identify the difference between the efficacy of
the two treatment modalities based on the anatomical
effect on OCT scan (absence of SRF versus still SRF vis-
ible). As we expect one treatment to be superior to the
other, this study is designed to be a superiority study.
Statistical analysis on the primary parameter will be
performed by analyzing the relative risk by using a
cross-table comparing evaluation at 6 to 8 weeks after
treatment with baseline.
Multivariate analysis
Analysis for the secondary endpoints For the second-
ary endpoints, the following analyses will be performed:
1. Anatomic results based on OCT scan (absence of
SRF versus persistent SRF) at evaluation point 1 will
be compared to the baseline.
2. Number of subsequent treatments needed in each
treatment arm.
3. Mean change from baseline in ETDRS BCVA in the
study eye at 6 to 8 weeks after treatment and at the
end evaluation will be compared between the two
treatment modalities.
4. Mean change from evaluation point 1 in ETDRS
BCVA in the study eye at final evaluation among
those with subsequent and those without
subsequent treatment will be compared between
the two treatment modalities
5. Mean change from baseline in retinal sensitivity in
the study eye to 6 to 8 weeks after treatment will be
compared between the two treatment modalities.
6. Mean change from baseline in the NEI-VFQ-25
questionnaire to 6 to 8 weeks after treatment will be
compared among the two treatment modalities.
The first two analyses will be performed by the use of
a cross-table. Furthermore, the continuous secondary
variables will be analyzed using an ANCOVA model
with baseline as and treatment as factor. For categorical
secondary endpoints, a chi-square test will be per-
formed. In addition, a logistic model with baseline as co-
variate and treatment as factor will be performed. The
change from baseline in the NEI-VFQ-25 questionnaire
results will be summarized descriptively.
Interim analysis
A formal interim analysis will be performed when 78
participants received the first evaluation at 6 to 8 weeks
after treatment. Statistical analysis on the primary par-
ameter will be performed by analyzing the relative risk
by using a cross-table comparing evaluation at 6 to
8 weeks after treatment with baseline.
Number of participants
Justification of sample size: total number of patients is
156
For HSML, an anatomic success rate of approximately
50 %, defined as no SRF on OCT, after 6 to 8 weeks may
be estimated based on retrospective studies [48, 56]. For
half-dose PDT, approximately 80 % anatomic success
may be estimated [18, 26–35]. Taking such a difference
of 30 % in treatment success into account, a power cal-
culation indicates that one would need 40 patients per
treatment arm (power: 80 %, α: 0.05). However, when we
also correct for factors such as positive publication bias
and our own empiric treatment experience, we expect to
find a difference in treatment success rate of approxi-
mately 22 % in favor of half-dose PDT. If we take one in-
terim analysis into account, according to the O’Brien-
Fleming method, 78 patients per treatment arm would
be required (power: 80 %, α: 0.05).
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Distribution of subjects per site
*group 1 (78 patients): half-dose PDT with Visudyne™
*group 2 (78 patients): HSML
The level of statistical significance
For the primary endpoint, the overall null hypothesis is
as follows:
H0 : probabilities of success are the same in both treat-
ment arms (π1 = π2)
versus
H1 : probabilities of success are different in the treat-
ment arms (π1 ≠ π2)
For statistical testing, the significance level will be 0.05
unless specified otherwise.
Criteria for the termination of the trial
The DMC will perform a review of the study data every
3 months. The study may be terminated prematurely on
the recommendation of the DMC. Reasons for prema-
ture termination of the trial may include the following:
1. Early solid statistical evidence that the
investigational medicinal product (IMP) is
significantly better than the comparator.
2. Early evidence that one or both treatments are
harmful.
Ethics
Declaration of Helsinki
The Chief Investigator will ensure that this study is con-
ducted in accordance with the principles of the 2008
Declaration of Helsinki.
ICH guidelines for good clinical practice
The investigator will ensure that this study is conducted
in full conformity with relevant regulations and with the
ICH guidelines for good clinical practice (CPMP/ICH/
135/95) July 1996.
Approvals
The protocol, informed consent form, participant infor-
mation sheet, and any proposed advertising material was
submitted to and received written approval from the
appropriate research ethics committees (REC) (see list
below), regulatory authorities, and host institution(s).
This trial has been internationally registered at Clinical-
trials.gov (NCT01797861; ClinicalTrials.gov).
The research ethical committees that have approved
the study protocol at the different sites are listed below:
1. The Commissie Mensgebonden Onderzoek (CMO)
Regio Arnhem-Nijmegen approved the protocol for
the following locations:
Radboud University Medical Center, Nijmegen, the
Netherlands, and
Leiden University Medical Center, Leiden, the
Netherlands.
2. The Ethik Kommission Universität zu Köln
approved the protocol for the following location:
University Hospital Cologne, Cologne, Germany.
3. The Health Research Authority National Research
Ethics Service (NRES) Committee South Central –
Oxford A approved the protocol for the following
location:
Oxford Eye Hospital, Oxford, United Kingdom
4. The Comité de Protection des Personnes Ile de
France V approved the protocol for the following
location:
University Paris Est Creteil, Paris, France
Discussion
To establish the optimal treatment for cCSC, an eye dis-
ease associated with potentially severe visual disability, a
multicenter prospective randomized controlled trial is
mandatory but currently lacking. The proposed study is
the first multicenter, prospective, randomized controlled
trial that compares half-dose PDT with HSML treatment
with regard to their ability to reduce SRF accumulation
in cCSC, and their ability to improve the quality of
vision. We have chosen to adopt half-dose PDT treat-
ment instead of half-fluency PDT treatment. A reduc-
tion of the dose of verteporfin, rather than the fluency
of the laser treatment, appears preferable because a
dose reduction may reduce possible systemic side ef-
fects of PDT treatment, such as lower back pain and
photosensitivity of the skin in the first days after treat-
ment [57], while having an efficacy comparable to half-
fluency PDT [58, 59].
HSML treatment has been chosen as the treatment of
choice in the control arm for a number of reasons. First,
sham (no treatment) was studied by Chan and co-workers
in the acute form of CSC, who showed a large difference
in anatomic and functional outcome (complete resolution
of SRF) between the half-dose PDT and placebo group
[60]. As it is well established that prolonged leakage of
SRF under the macula due to cCSC may lead to perman-
ent visual loss, it is not desirable to include comparison
with sham in our study [8–10, 20, 25, 60–65]. HSML
treatment of CSC has been shown to be effective and
Netherlands
(Nijmegen/Leiden)
Oxford (UK)/Cologne
(Germany)/Paris (France)
Group 1* 50 subjects 28 subjects
Group 2* 50 subjects 28 subjects
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safe in 41-58 % of patients in smaller, retrospective
studies [18, 48, 56]. The safety and efficacy of HSML
treatment has also been reported in various other ret-
inal diseases [49]. In contrast, it has been shown that
conventional laser treatment of focal leakage point on
fluorescein angiography in CSC does not result in a
better visual outcome [3, 41]. Also, conventional laser
treatment in CSC has a higher risk of complications
than HSML and half-dose PDT, including vision loss,
scotoma, decreased color vision, decreased contrast
sensitivity, and choroidal neovascularization [2, 41, 66].
The 810 nm HSML laser modality was chosen instead
of the 577 nm wavelength because at the time of the
start of the study, relatively little had been published on
the safety and efficacy of 577 nm HSML, and experi-
mental studies between 810 nm and 532 nm micropulse
laser strategies have not shown obvious differences in
histological effect [67].
Trial status
The first participant was recruited on 18 December
2013, and the estimated study completion date is June
2017.
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